HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (15) Citing Articles via Google Scholar Google Scholar Articles by Merkus, P.J.F.M. Articles by de Jongste, J.C. Search for Related Content PubMed PubMed Citation Articles by Merkus, P.J.F.M. Articles by de Jongste, J.C.

DNase treatment for atelectasis in infants with severe respiratory syncytial virus bronchiolitis

¹ Dept of Paediatrics, subdivision of Respiratory Medicine, and ² Paediatric Intensive Care, Sophia Children's Hospital, Erasmus Medical Centre Rotterdam, and ³ Dept of Paediatrics, Sint Joseph Hospital, Veldhoven, the Netherlands

CORRESPONDENCE: P.J.F.M. Merkus, Sophia Children's Hospital/Erasmus Medical Centre Rotterdam, PO Box 2060, 3000 CB, Rotterdam, the Netherlands. Fax: 31 104636801

Keywords: atelectasis, bronchiolitis, infants, recombinant human deoxyribonuclease, respiratory failure, respiratory syncytial virus

Received: March 28, 2000
Accepted May 24, 2001

Abstract

Respiratory insufficiency due to respiratory syncytial virus (RSV) bronchiolitis is partly due to the abundance of thickened mucus and the inability to clear it from the airways. Mucus in RSV bronchiolitis contains necrotic inflammatory and epithelial cells. The viscoelastic properties of purulent airway secretions are largely due to the presence of highly polymerized deoxyribonucleic acid (DNA). Recombinant human deoxyribonuclease (rhDNase) is known to liquefy such mucus in patients with cystic fibrosis, whereas case reports described a beneficial effect in other respiratory disorders. The authors hypothesized that rhDNase would diminish atelectasis and mucus plugging in infants with severe RSV bronchiolitis.

Two infants with RSV bronchiolitis with massive unilateral atelectasis in whom mechanical ventilation was imminent due to exhaustion, and three mechanically ventilated infants (two neonates, one with bronchopulmonary dysplasia) with RSV bronchiolitis with pneumonia received treatment with 2.5 mg nebulized rhDNase twice daily.

Following administration of nebulized recombinant human deoxyribonuclease, clinical and radiological parameters improved quickly. Mechanical ventilation could be avoided in two infants while in three infants on artificial ventilation, clinical recovery started following the first dose of the drug. A therapeutic trial of recombinant human deoxyribonuclease may be an option in the treatment for atelectasis in severe or complicated respiratory syncytial virus bronchiolitis in infancy.

This article has been cited by other articles:

				R. Boogaard, A. R. Hulsmann, L. van Veen, A. A. P. H. Vaessen-Verberne, Y. N. Yap, A. J. Sprij, G. Brinkhorst, B. Sibbles, T. Hendriks, S. W. W. Feith, et al. Recombinant Human Deoxyribonuclease in Infants With Respiratory Syncytial Virus Bronchiolitis Chest, March 1, 2007; 131(3): 788 - 795. [Abstract] [Full Text] [PDF]